Background/Purpose: The present study aimed to assess whether SRT to the prostatic fossa should be initiated in a timely manner after detecting biochemical recurrence (BR) in patients with prostate cancer, when no correlate was identified with prostate-specific membrane antigen positron emission tomography (PSMA-PET). Materials and Methods: This retrospective, multicenter analysis included 1222 patients referred for PSMA-PET after a radical prostatectomy due to BR. Exclusion criteria were: pathological lymph node metastases, prostate-specific antigen (PSA) persistence, distant or lymph node metastases, nodal irradiation, and androgen deprivation therapy (ADT). This led to a cohort of 341 patients. Biochemical progression-free survival (BPFS) was the primary study endpoint. Results: The median follow-up was 28.0 months. The 3-year BPFS was 71.6% in PET-negative cases and 80.8% in locally PET-positive cases. This difference was significant in univariate (p = 0.019), but not multivariate analyses (p = 0.366, HR: 1.46, 95%CI: 0.64–3.32). The 3-year BPFS in PET-negative cases was significantly influenced by age (p = 0.005), initial pT3/4 (p < 0.001), pathology scores (ISUP) ≥ 3 (p = 0.026), and doses to fossa > 70 Gy (p = 0.027) in univariate analyses. In multivariate analyses, only age (HR: 1.096, 95%CI: 1.023–1.175, p = 0.009) and PSA-doubling time (HR: 0.339, 95%CI: 0.139–0.826, p = 0.017) remained significant. Conclusion: To our best knowledge, this study provided the largest SRT analysis in patients without ADT that were lymph node-negative on PSMA-PET. A multivariate analysis showed no significant difference in BPFS between locally PET-positive and PET-negative cases. These results supported the current EAU recommendation to initiate SRT in a timely manner after detecting BR in PET negative patients.

Salvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence- results of a retrospective study / Scharl S.; Zamboglou C.; Strouthos I.; Farolfi A.; Serani F.; Lanzafame H.; Giuseppe Morganti A.; Trapp C.; Koerber S.A.; Debus J.; Peeken J.C.; Vogel M.M.E.; Vrachimis A.; Spohn S.K.B.; Ruf J.; Grosu A.-L.; Ceci F.; Fendler W.P.; Bartenstein P.; Kroeze S.G.C.; Guckenberger M.; Krafcsik M.; Klopscheck C.; Fanti S.; Hruby G.; Emmett L.; Belka C.; Stief C.; Schmidt-Hegemann N.-S.; Henkenberens C.; Mayer B.; Miksch J.; Shelan M.; Aebersold D.M.; Thamm R.; Wiegel T.. - In: RADIOTHERAPY AND ONCOLOGY. - ISSN 0167-8140. - STAMPA. - 184:(2023), pp. 109678.109678-109678.109678. [10.1016/j.radonc.2023.109678]

Salvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence- results of a retrospective study

Serani F.;Fanti S.;
2023

Abstract

Background/Purpose: The present study aimed to assess whether SRT to the prostatic fossa should be initiated in a timely manner after detecting biochemical recurrence (BR) in patients with prostate cancer, when no correlate was identified with prostate-specific membrane antigen positron emission tomography (PSMA-PET). Materials and Methods: This retrospective, multicenter analysis included 1222 patients referred for PSMA-PET after a radical prostatectomy due to BR. Exclusion criteria were: pathological lymph node metastases, prostate-specific antigen (PSA) persistence, distant or lymph node metastases, nodal irradiation, and androgen deprivation therapy (ADT). This led to a cohort of 341 patients. Biochemical progression-free survival (BPFS) was the primary study endpoint. Results: The median follow-up was 28.0 months. The 3-year BPFS was 71.6% in PET-negative cases and 80.8% in locally PET-positive cases. This difference was significant in univariate (p = 0.019), but not multivariate analyses (p = 0.366, HR: 1.46, 95%CI: 0.64–3.32). The 3-year BPFS in PET-negative cases was significantly influenced by age (p = 0.005), initial pT3/4 (p < 0.001), pathology scores (ISUP) ≥ 3 (p = 0.026), and doses to fossa > 70 Gy (p = 0.027) in univariate analyses. In multivariate analyses, only age (HR: 1.096, 95%CI: 1.023–1.175, p = 0.009) and PSA-doubling time (HR: 0.339, 95%CI: 0.139–0.826, p = 0.017) remained significant. Conclusion: To our best knowledge, this study provided the largest SRT analysis in patients without ADT that were lymph node-negative on PSMA-PET. A multivariate analysis showed no significant difference in BPFS between locally PET-positive and PET-negative cases. These results supported the current EAU recommendation to initiate SRT in a timely manner after detecting BR in PET negative patients.
2023
Salvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence- results of a retrospective study / Scharl S.; Zamboglou C.; Strouthos I.; Farolfi A.; Serani F.; Lanzafame H.; Giuseppe Morganti A.; Trapp C.; Koerber S.A.; Debus J.; Peeken J.C.; Vogel M.M.E.; Vrachimis A.; Spohn S.K.B.; Ruf J.; Grosu A.-L.; Ceci F.; Fendler W.P.; Bartenstein P.; Kroeze S.G.C.; Guckenberger M.; Krafcsik M.; Klopscheck C.; Fanti S.; Hruby G.; Emmett L.; Belka C.; Stief C.; Schmidt-Hegemann N.-S.; Henkenberens C.; Mayer B.; Miksch J.; Shelan M.; Aebersold D.M.; Thamm R.; Wiegel T.. - In: RADIOTHERAPY AND ONCOLOGY. - ISSN 0167-8140. - STAMPA. - 184:(2023), pp. 109678.109678-109678.109678. [10.1016/j.radonc.2023.109678]
Scharl S.; Zamboglou C.; Strouthos I.; Farolfi A.; Serani F.; Lanzafame H.; Giuseppe Morganti A.; Trapp C.; Koerber S.A.; Debus J.; Peeken J.C.; Vogel M.M.E.; Vrachimis A.; Spohn S.K.B.; Ruf J.; Grosu A.-L.; Ceci F.; Fendler W.P.; Bartenstein P.; Kroeze S.G.C.; Guckenberger M.; Krafcsik M.; Klopscheck C.; Fanti S.; Hruby G.; Emmett L.; Belka C.; Stief C.; Schmidt-Hegemann N.-S.; Henkenberens C.; Mayer B.; Miksch J.; Shelan M.; Aebersold D.M.; Thamm R.; Wiegel T.
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/957698
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 6
  • ???jsp.display-item.citation.isi??? ND
social impact